See referenced original article on pages 327-35, this issue.
Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia†
Before or after imatinib?
Article first published online: 26 OCT 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 2, pages 234–237, 15 January 2011
How to Cite
Tefferi, A. (2011), Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia. Cancer, 117: 234–237. doi: 10.1002/cncr.25600
- Issue published online: 5 JAN 2011
- Article first published online: 26 OCT 2010
- Manuscript Accepted: 20 JUL 2010
- Manuscript Received: 8 JUL 2010
Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.